 Patients will be treated for Osteoarthritis due to degeneration or chronic injury. They will be given autologous SVF extract derived by the A3 method mixed with activated platelets from a PRPplatelet rich plasma preparation as direct injections to the effected joints. Outcomes will be tracked with WOMAC Western Ontario and McMaster Universities Arthritis Index, AUSCANAustralian Hand Osteoarthritis Index scores, and a general blood panel in order to evaluate systemic effects. 